Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
ARCHIVE
Astellas Licenses Transplant Viremia Prevention Vaccine from Vical
Astellas Pharma announced on July 15 that it concluded a license agreement with Vical Inc. of the US and obtained exclusive worldwide development and commercializing rights to Vical's TransVax, a therapeutic vaccine designed to control cytomegalovirus (CMV) viremia in transplant…
To read the full story
Related Article
- Astellas/Vical’s CMV Vaccine Flops in Global PIII
January 23, 2018
- Astellas-Vical’s CMV Vaccine Disappoints in PII for Kidney Transplant Patients
September 21, 2016
ARCHIVE
- Pharmaceutical Industry Salary Survey 2011
December 26, 2011
- AFII Grants France-Japan Investment Award to sanofi-aventis, Canon
December 19, 2011
- Plan Like Your Life Depended on It… It Just Might!
December 5, 2011
- Interviewing and Hiring: Strong Character Plus Good Attitude Equals Great Potential
November 14, 2011
- A Cry from the Next Generation of Japanese Pharmaceutical Executives
October 24, 2011
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…